*Use a blood glucose meter to confirm any highs or lows and when your symptoms do not match your sensor’s readings.
**In a trial where Dexcom G6 powered the Tandem hybrid closed-loop system with Control-IQ, participants with TID increased their time in range (TIR) by an average of 2+ hours per day. Kovatchev B, et al. N Engl J Med 2019;381(18):1707-17. Individual results may vary.
†Reduction of A1C by 1.0% for Patients with T1D. Dexcom CGM System users on a multiple daily injections (MDI) insulin regimen showed an average A1C reduction of 1% after 24 weeks of regular use, compared to baseline. Additionally, 52% of subjects in the study had a ≥1% A1C reduction. Beck RW, et al. JAMA. 2017;317(4):371-378. Significant A1C Reduction for Patients with T2DPatients with T2D on mealtime insulin achieved an average 1.5% A1C reduction after using Dexcom G6 for 12+ weeks. Noar A, et al. A1C Reductions and Improved Patient-Reported Outcomes Following CGM Initiation in Insulin-Managed T2D. Presented at ADA 80th Scientific Sessions; June 12, 2020; Virtual. Individual results may vary.
††Check glucose levels up to 1,440 times per day on the FreeStyle Libre 2 System and up to 288 times per day on the Dexcom G6.
¹For qualified persons with applicable in-network insurance and subject to CGM coverage requirements. Deductibles, co-pays, and other conditions apply. Speak to a HEALTHCARE DME representative and your insurance company to confirm your coverage and costs. CGM devices have safety requirements, warnings, and instructions. Consult the manufacturer websites for details. Seek medical advice and attention when appropriate, including for any medical emergency.